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Summary Comparative genomic hybridization (CGH) was used to detect copy number changes of DNA sequences in the Ewing family of
tumours (ET). We analysed 20 samples from 17 patients. Fifteen tumours (75%) showed copy number changes. Gains of DNA sequences
were much more frequent than losses, the majority ofthe gains affecting whole chromosomes orwhole chromosome arms. Recurrentfindings
included copy number increases for chromosomes 8 (seven out of 20 samples; 35%), 1q (five samples; 25%) and 12 (five samples; 25%).
The minimal common regions of these gains were the whole chromosomes 8 and 12, and 1q21-22. High-level amplifications affected
8q13-24, 1q and 1q21-22, each once. Southern blot analysis of the specimen with high-level amplification at 1q21-22 showed an
amplification of FLG and SPRR3, both mapped to this region. All cases with a gain of chromosome 12 simultaneously showed a gain of
chromosome 8. Comparison of CGH findings with cytogenetic analysis of the same tumours and previous cytogenetic reports of ET showed,
in general, concordant results. In conclusion, our findings confirm that secondary changes, which may have prognostic significance in ET, are
trisomy 8, trisomy 12 and a gain of DNA sequences in 1q.
Keywords: Ewing family of tumours; comparative genomic hybridization; 1q; chromosome 8; chromosome 12
Ewing's sarcoma is the most frequent bone tumour in children
under 10 years of age and the third most common primary malig-
nant bone tumour in adults. It is most commonly located in the
bone, but it can also arise in soft tissues. Ewing's sarcoma is
closely related to peripheral neuroepithelioma, Askin's tumour
and aesthesioneuroblastoma. These tumours are referred to as the
Ewing family of tumours (ET), which characteristically show a
high expression ofthe MIC2 antigen (Ambros et al, 1991).
A specific chromosomal abnormality, t(11;22)(q24;ql2), is
consistently found in ET (Turc-Carel et al, 1988). It fuses EWS, a
previously uncharacterized gene in 22q12, with FLI1 in 11q24 and
generates a hybrid transcript (Delattre et al, 1992). In few cases,
the EWS gene may be fused with other genes, e.g. ERG on chro-
mosome 21 orETVJ on chromosome 7 (Zucman et al, 1993; Jeon
et al, 1995), both members of the ETS family of transcription
factors, like FLII. The t(I11;22) or a variant translocation affecting
either llq24 or 22q12 has been described in 90% of the cases
(Mitelman, 1994).
Other chromosomal abnormalities, without the specificity ofthe
primary change, have been detected repeatedly in ET. These
secondary changes contribute to tumour progression and may
serve as criteria for the aggressiveness of the disease (Mugneret
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et al, 1988). The most common additional changes are trisomies
8 and 12, and der(1;16). This derivative chromosome often leads
to trisomy for lq. Trisomy 8 has been observed in 44% ofthe cases
(Mugneret et al, 1988), trisomy 12 in 29% (Hattinger et al, 1996)
and der(1;16) in 18% (Douglass et al, 1990).
Conventional cytogenetic analysis is often difficult in ET owing
to the low number ofmitotic cells, poor chromosome morphology
and banding, and the complex nature of chromosomal changes.
Our aim was to evaluate the incidence of the above-mentioned
and other non-random additional changes in ET by comparative
genomic hybridization (CGH). CGH makes it possible to identify
genomic imbalances with tumour DNA as the only requirement.
This method is based on the hybridization ofdifferentially labelled
tumour DNA and normal DNA to normal metaphase spreads
(Kallioniemi et al, 1992). In the present study, we applied CGH to
a series ofETs.
MATERIALS AND METHODS
Tumour specimens
The study was carried out on 20 samples from 17 patients (two
specimens from the same patient in three cases). The tumour
samples and the respective clinical data are listed in Table 1. Some
samples were from frozen tissues and some from paraffin sections
(cases 15, 16 and 17). The DNAs from the paraffin-embedded
samples were extracted according to the protocol published by
Miller et al (1988) with slight modifications. The proportion of
tumour cells in the paraffin sections ranged from 70% to 95%. For
the fresh samples, it was not possible to obtain the corresponding
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Table 1 Clinical characteristics of 20 specimens of the Ewing family of tumours
Case Agea/ Primary Samples Metastases Treatmentd Survival,
no. sex tumourb at diagnosis
P/R/Mc Location
1a 24/F Soft tissue P Knee region - 46-
1b 24/F Soft tissue P Knee region +(C) 46-
2a 33/M Soft tissue P Calf +(Lung) - 55-
2b 33/M Soft tissue P Calf +(Lung) +(C) 55-
3 18/F Soft tissue P Shoulder blade region - - 63-
4 27/F Bone P Femur - 58-
5 18/M Bone M Humerus - +(C) 71t
6a 36/F Soft tissue P Ankle - 67-
6b 36/F Soft tissue P Ankle - +(C) 67-
7 18/F Soft tissue M Spine - +(C, R) 58t
8 19/F Bone P Pelvis - - 31t
9 49/F Bone M Abdominal subcutis +(*) - lit
10 33/F Soft tissue P Subcutis, thigh - - 86-
11 36/F Soft tissue P Buftock - - 30t
12 12/F Bone P Rib - - 52-
13 3/M Bone P Ulna - - 38-
14 16/M Bone R Pelvis +(Gastrointestinal) - 33t
15 34/M Bone R Humerus +(C, R) 70t
16 18/M Bone R Femur +(C, R) 32t
17 26/F Bone P Rib** - 26t
aAge at diagnosis in years. F, female; M, male. bCase 6, atypical Ewing's sarcoma; case 9, peripheral primitive neuroectodermal tumour; all the other tumours
were typical Ewing's sarcomas. cp, primary tumour; R, recurrent tumour; M, metastasis. dTreatment before the operation. C, chemotherapy; R, radiation.
eMonths from diagnosis. -, no evidence of disease; t, dead of disease. *Mediastinum, abdominal cavity, caput of pancreas, abdominal subcutis, Si-joint region
with destruction of the pelvic bone. "With pleural and soft-tissue infiltration.
histology, but these samples were always taken with great care
from representative areas ofthe tumours. All cases were re-evalu-
ated by two pathologists (MV and TB) and classified as belonging
to theEwing family oftumours based on histology, staining for the
MIC2 gene product (Dako, Glostrup, Denmark) and/or diagnostic
findings in the chromosome analysis. Case 6 represents an atypical
Ewing's sarcoma, case 9 a peripheral primitive neuroectodermal
tumour and the rest typical Ewing's sarcoma (Navarro et al, 1994).
Labelling procedures for CGH experiments
The DNA samples were labelled by direct and indirect methods.
Indirect labelling was used for frozen tumour samples and direct
for paraffin-embedded tumour samples. In the indirect method,
reference DNA from healthy blood donors and tumour DNA were
labelled with digoxigenin-l1-dUTP (Boehringer Mannheim,
Germany) and biotin-14-dATP (Gibco BRL, Gaithersburg, MD,
USA) respectively. For the direct method, the normal DNA was
labelled with Texas red-5-dUTP (DuPont, Boston, MA, USA) and
the tumour DNA with fluorescein-12-dUTP (DuPont). Standard
nick translation procedures were used in both.
Comparative genomic hybridization
Thehybridizations were performed as described by Kallioniemi et al
(1994) with some modifications. Briefly, equal amounts of the two
DNAs (500 ng) and 10 ig ofhuman Cot-l DNA (Gibco BRL) were
ethanolprecipitated andredissolved in 10glof50% formamide/10%
dextran sulphate/2 x saline sodium citrate (SSC). Normal lympho-
cyte metaphase preparations were denatured at 68-69°C for2 min in
a formamide solution (70% formamide/2 x SSC, pH 7), dehydrated
and treated with proteinase K (0.1 jIg ml-' in 20 mM Tris-HCI/2 mM
calcium chloride, pH 7) at 37°C for 7.5 min and dehydrated again.
The probe mixture was denatured at 75°C for 5 min, applied to the
slides and hybridized for 2-3 days at 37°C.
After the hybridization the slides were washed. In indirect
labelling, tumour DNA was detected with tetraethylrhodamine
isothiocyanate (TRITC) conjugated to avidin, and normal DNA
with fluorescein isothiocyanate (FITC) anti-digoxigenin.
Chromosomes were counterstained with 10 jig ml-1 4',6-diamidino-
2-phenylindole (DAPI) and mounted in an anti-fade solution.
Digital image analysis
The hybridizations were analysed using an Olympus fluorescence
microscope and the isis digital image analysis system
(MetaSystems, Altlussheim, Germany) based on a high-sensitivity
integrating monochrome CCD camera and an automated CGH
analysis software package.
Interpretation of CGH results and quality control
Ratio profiles were averaged from between five and ten metaphases
per sample (up to 20 chromosome homologues). Gains of DNA
sequences were defined as chromosomal regions with a fluores-
cence ratio above 1.17, and losses as regions with a ratio below
0.85. These cut-off values were based on negative control experi-
ments with normal DNAs using both indirect and direct labelling.
In these hybridizations, the fluorescence ratios stayed between 0.85
and 1.17. Alternative statistical thresholds based on the t-distribu-
tion ofthe ratio value ofbalanced chromosomes were also applied.
Chromosomal imbalances were confirmed by a 99% confidence
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interval. A positive control with known aberrations and a negative
control were included in each CGH experiment as quality controls.
A ratio over 1.5 was considered to represent a high-level DNA
amplification. Heterochromatic regions (lql2, 9ql2, 16ql1, 13p,
14p, 15p, 21p, 22p and Y chromosome) were excluded from the
analysis. The profiles of lp32-pter, 16p, 17p and chromosomes 19
and 22 were interpreted with caution, because they have been
known to give false-positive results (Kallioniemi et al, 1994).
Conventional cytogenetic analysis and interphase
in situ hybridization
The methods used for conventional and interphase cytogenetics
have been described previously (Tarkkanen et al, 1993).
Southern blot analysis
Preparation of filter blots and hybridization were performed as
described previously (Forus et al, 1993). Quantitation of signal
intensity was done by two-dimensional densitometry on a
Molecular Dynamics laser densitometer. The net signals from
specific bands were corrected for unequal sample loading by cali-
bration relative to the signal obtained with an APOB control probe
and compared with signals from control samples with a normal
copy number of the gene (leucocytes). The probes used from
lq21-22 were a cDNA from the SPRR3 gene (Gibbs et al, 1993;
Hohl et al, 1995), kindly provided by Dr Backendorf, and pHC5
FLG (Presland et al, 1992), containing a part of the coding region
from the 3' end of the human filaggrin gene, kindly provided by
Drs Fleckman and Presland. A cDNA probe for the APOB gene on
human chromosome 2, kindly provided by Dr Breslow (Huang et
al, 1985), was used to calibrate for unequal sample loading.
Statistical analyses
The 5-year survival in patients with and without copy number
increases in lq21-22 and in chromosomes 8 and 12 in primary
tumours was estimated with the Kaplan-Meier method and the
statistical significance tested by the log-rank method. The correla-
tion between overall survival and total number of aberrations in
CGH was estimated by the Cox proportional hazards model and
the statistical significance with the Wald test.
RESULTS
Comparative genomic hybridization
All DNA sequence copy number changes detected by CGH and
chromosome banding data have been listed in Table 2. Fifteen out
of the 20 samples (75%) presented DNA sequence copy number
changes. Thirteen tumours (65%) showed gains of DNA
sequences and five (25%) showed losses. These changes were
present at one or more chromosomal sites. On average, there were
2.3 aberrations per sample (range 0-9): 1.9 gains (range 0-9) and
0.4 losses (range 0-2). The mean number of aberrations was 1.5
per sample in primary tumours and in the group of tumour recur-
rences and metastases 4.4. Gains and losses of whole chromo-
somes or whole chromosome arms were common (71% of all
changes). Three tumours showed high-level amplifications
(ratio > 1.5). Figure 1 presents the summary of all chromosomal
regions with an increased or decreased DNA sequence copy
number. The most frequent changes were gains of chromosomes
8 and 12, and gains in the long arm ofchromosome 1. Examples of
the fluorescence ratio profiles ofthese chromosomes are illustrated
in Figure 2.
Table 2 CGHa and cytogenetic results in 20 samples of the Ewing family of tumours
Case no.b Cytogenetic data CGH datac
1a 50, XX, +8, t(10;?)(q?;q?), t(11 ;22)(q24;q12), +12, +14, +21 [21] +1q21-22, +8, +12, +14q, +21q
lb 45-50, XX, +8, ?t(11 ;22)(q24;q12), inc [5]/46, XX nca*[3] Normal
2a 46, XY, t(11;22)(q24;q12) [1]/46, idem, +der(1;16)(q1O;pl0),-16 [7] Normal
2b Not available Normal
3 46, XX, del(1)(p?33p?35), add(11)(q12), add(22)(q12) [10] Normal
4 46-47, XX,-1,-2,-5, add(11)(p?15), ?t(11;22)(q24;q12), +?21, +3mar, inc [cp 12] +4q27-33, +7q, -11q21-25, -16
5 46, XY [3] +14q22-32
6a 46, XX [10] -3q
6b 46, XX [1] -3q13.3-29
7 49-52, XX, del(2)(p?21), +add(5)(q?23), del(6)(q?12q?16), +lq, +5, +8/8q13-24, +12, +20q11.2-13.1
-9, t(11 ;22)(q24;q12), der(13;13)(ql O;q10), add(14)(q?32),
-17, ?add(19)(ql 3), add(20)(q13), +21, +4-5mar [cp8]/44-46, XX,
del(1)(p?32p?36), add(4)(p?12), del(9)(q22), -14, add(19)(ql3), +1-2mar [cp2]
8 46-48, XX, +3-4mar, inc [14] -1p13-36, +1q21-31, -9p
9 47, XX, -4,-10,-15, del(22)(q?12), +3-4mar, inc [4] +lq/1q21-22, -6q14-25, +7p22-qll.2, +9q
10 42-46, XX, -16, +marl, +mar2 [cp5]/46, XX [5] +16q
11 47, XX, +mar, inc [cp6]/46, XX [2] +6, +8
12 46, XX, -1,-11,-22, +marl, +mar2, +mar3 [cpl9] Normal
13 51-54, +B, +C, +D, +mar, inc [11]/46, XY [11] +8
14 47, XY, +i(1)(qlO), t(11;22)(q24;q12) [10] +1q
15 Not available +2p21-q37, +4, +5p12-15.1, +6, +7, +8, +12,
+13q14-34, +18q
16 Not available +8, +12, +21q21-22
17 Not available +4, +8, +12, +14q13-32
aCGH, comparative genomic hybridization. bCases 1-14 from frozen tumour tissue samples and cases 15-17 from paraffin sections. cHigh-level amplifications
are shown in bold. *nca, non-clonal aberrations.
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Figure 1 Summary of gains (right) and losses (left) of DNA sequences detected by CGH in 20 samples belonging to the Ewing family of tumours. Two
specimens (a and b) are from patient 6. High-level amplifications are represented by thick bars
Chromosome 8 was involved in copy number increases in seven
tumours (35%). These gains always affected the entire chromo-
some. One ofthe tumours with a gain ofthe whole chromosome 8
had a high-level amplification in 8ql3-24. Five tumours (25%)
showed a gain in some region of lq. Three of these were gains of
the whole q-arm (two with a high-level amplification), and the
other two showed gains at smaller sites. The minimal common
region was lq21-22, highly amplified in two cases. DNA
sequences in the long arm of chromosome 1 and the whole chro-
mosome 8 were simultaneously gained in two samples (cases la
and 7). Five tumours (25%) presented a gain of chromosome 12,
always affecting the entire chromosome. The gain ofchromosome
12 was accompanied in all cases by again ofchromosome 8. Copy
number increases were also detected in other chromosomal sites,
but at a lower frequency. Regions on 4q and 14q showed gains
of DNA sequences in three samples each, whereas other chromo-
somal regions showed copy number increases only in one or
two cases.
Regional copy number losses were detected in six different
chromosomes, but only in one case each.
Conventional cytogenetic analysis and interphase
in situ hybridization
Cytogenetic analysis was performed in 16 samples (Table 2). Three
tumours (2a, 3 and 4) have been reported previously (Tarkkanen et
al, 1993). Clonal aberrations were detected in 13 cases, of which
six had the typical t( 1;22)(q24;q12). In three tumours, the aberra-
tions involved chromosome 11 and/or22, indicating most probably
the involvement of llq24 and/or 22q12. In four cases, the exact
characterization ofthe clonal aberrations was notpossible owing to
poor chromosome morphology and banding and the scarcity of
mitotic cells. The der(l;16)(qlO;plO) in case 2a was confirmed by
interphase in situ hybridization with a centromere-specific probe
for chromosome 1 as reported previously (Tarkkanen et al, 1993).
Three signals were observed in 30% ofthe cells.
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Figure 2 Ratio profiles obtained from the CGH analysis of the Ewing family
of tumours. Pictured profiles are those of the chromosomes with the most
frequent changes. The line in the middle of the profile indicates the base line
ratio (1.0), the lines on the left and right indicate ratio values of 0.85 and
1.17. The aberrations shown are high-level amplification of 1q (case 14), gain
of chromosome 8 (case 13) and gain of chromosome 12 (case 17)
Southern blot analysis
Case 9 with a high-level amplification at lq21-22 was analysed
for amplification of two genes in lq21-22, SPRR3 and FLG,
which have previously been found to be amplified in some
sarcoma samples (Forus et al, 1996). As shown in Figure 3, both
genes were amplified: the signal from FLG was 2.7-fold increased
compared with the normal sample and the signal from SPRR3 was
2.1-fold increased (i.e. at least five and four copies respectively).
Statistical analyses
The estimated 5-year survival rate was 78% and 50% in cases
without and with a copy number increase at 1q21-22 (P = 0.57),
84% and 50% in cases without and with a copy number increase of
chromosome 8 (P = 0.16), and 78% and 50% in cases without and
with again ofchromosome 12 (P = 0.3). There was no statistically
significant (P = 0.24) correlation between overall survival and the
number ofaberrations detected by CGH.
DISCUSSION
This study represents the first genome-wide screening of losses
and gains ofDNA sequences in the Ewing family oftumours (ET).
Copy number changes were detected in 15 out of 20 tumours
(75%). The most frequent changes include gains ofthe long arm of
chromosome 1 and the whole chromosomes 8 and 12. The low
mean number ofaberrations, 2.3 per sample, is probably due to the
importance of the translocation t(I1;22), not detectable by CGH,
but may also be caused by normal cell contamination or intra-
tumoral genetic heterogeneity. Copy number changes were
detected in all paraffin-embedded tumour samples that are charac-
terized by a high proportion oftumour cells.
A gain of chromosome 8 was observed in 35% of the tumours.
This abnormality revealed by CGH confirms previous cytogenetic
findings: trisomy 8 has been reported in 44% ofthe ET (Mugneret
et al, 1988). Our CGH results suggest that the main region is
smaller and located at 8ql3-q24, according to the high-level
amplification that was found. This area possibly harbours putative
oncogene(s) important in the development and progression of ET.
Band 8q24 contains MYC, which is known to have an elevated
SPRR3 FLG APOB
Figure 3 DNA (7 gg) from case 9 was digested with Hindlll and sequentially
hybridized to probes as indicated. Leucocyte DNA was included as a control
for normal copy number, and a probe for APOBwas used to calibrate for
unequal sample loading. Signals from FLG and SPRR3were found to be
2.7-fold and 2.1-fold increased, respectively, when compared with average
signals from six normal samples
level of expression in Ewing's sarcoma and related tumours
(McKeon et al, 1988). However, it is difficult to establish the role
of individual genes when DNA sequence copy number changes
affect large regions, because the dosage of numerous genes could
be altered simultaneously.
Recurrent gains were also observed in the long arm ofchromo-
some 1 (25%). The gain of DNA sequences in lq is according to
conventional cytogenetic studies of ET. An unbalanced t(1;16)
resulting in a non-random derivative chromosome with an extra
copy of lq has been present in 18% of the samples studied
(Mugneret et al, 1988; Douglass et al, 1990). By CGH, the
minimal common region is lq21-22. Gains affecting this area
have also been reported in different types of soft-tissue sarcoma
and in osteosarcoma (Forus et al, 1995a,b; Tarkkanen et al, 1995;
Szymanska et al, 1996a). lq21-22 harbours several genes that
may contribute to the development and/or progression of human
sarcoma. For example, several members of the S-100 family of
calcium-binding proteins are clustered on lq21, e.g. CACY and
CAPL, the enhanced expression of which is associated with
tumour progression or metastasis (Engelkamp et al, 1993).
Recently, the amplification of FLG and SPRR3, located in lq21,
has been reported in some human sarcoma samples (Forus et al,
1996). As shown by the Southem blot analysis, these genes are
also amplified in case 9, which by the CGH analysis had a gain in
the whole long arm ofchromosome 1 with a high-level amplifica-
tion at lq21-22.
The present study also revealed gains ofthe entire chromosome
12 (25%). A recent study reported trisomy 12, detected by conven-
tional cytogenetics and in situ hybridization studies, in 29% ofET
(Hattinger et al, 1996). Several oncogenes have been mapped to
this chromosome, including SAS, CHOPIGADD153, GLI and
A2MR, frequently amplified in human sarcomas (Smith et al,
1992; Forus et al, 1993), and MDM2 and CDK4, known to be
amplified also in ET (Ladanyi et al, 1995). Even though all these
genes are located in a narrow area (12q13-15) (Mitchell et al,
1995), other studies in soft-tissue sarcomas have also shown other
regions of chromosome 12 involved in gains of DNA sequences,
such as 12q21-22 and 12q24 (Suijkerbuijk et al, 1994; Forus et al,
British Journal ofCancer(1997) 75(10), 1403-1409
Ob 1\
0 C' CP
1\ (b V
$S.
N)p
0 Cancer Research Campaign 19971408 G Armengol etal
1995b). Furthermore, microsatellite repeat analysis in the
12q13-22 region shows the presence of separate amplicons (Wolf
et al, 1997). These results support our findings of a gain of the
whole chromosome 12.
All cases with a gain of chromosome 12 also showed a gain of
the whole chromosome 8, this finding suggesting that a simulta-
neous gain of chromosomes 8 and 12 contributes to the tumori-
genesis and progression of ET. In addition, gains of 8q, lq and
12q have been described previously by CGH in osteosarcoma
(Tarkkanen et al, 1995), parosteal osteosarcoma (Szymanska et al,
1996b) and soft-tissue sarcomas (Suijkerbuijk et al, 1994; Forus et
al, 1995b; Szymanska et al, 1996a).
Losses were very rare and non-recurrent. There were five times
more gains than losses, which, together with the presence of some
highly amplified regions, suggests that gains of genetic material
are more significant than losses for the development and progres-
sion of ET.
In general, the data from CGH and cytogenetic analyses did not
show any disagreement. In cases la and 14, we obtained exactly
the same numerical changes by both methods. In the rest of the
samples, the poor quality of the chromosomes made it difficult to
determine the exact karyotype. The presence of markers and
multiple subclones may explain the differences between CGH and
cytogenetics in these samples. Furthermore, an interphase cyto-
genetic study with a centromere-specific probe for chromosome 1
was performed in one case with der(l;16)(qlO;p 0), which leads
to partial trisomies of lq and partial monosomies of 16q. The
abnormality was present only in 30% of the cells analysed
(Tarkkanen et al, 1993). The low frequency of the clone could
explain the normal karyotype found by CGH.
Our CGH analysis shows that many loci frequently show copy
number changes in ET. However, the critical and primary event in
the tumorigenesis of ET is most likely the t(I1;22) or a variant
translocation. The secondary abnormalities are the gain ofchromo-
somes 8 and 12, and the gain ofDNA sequences in lq, which agree
with cytogenetic studies. As one of the known translocations is a
likely primary event, it is possible that these additional changes may
have prognostic significance. Owing to the limited number ofcases
in the present study, testing of the statistical significance of the
prognostic effect ofthese changes is associated with a high risk ofa
type II statistical error. It is of interest to note, however, that copy
number increases in 1q and in chromosomes 8 and 12 were
all associated with (non-significant) trends to poor survival. To
evaluate this further, a larger numberofpatients needs to be studied.
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